What is the half-life of hydrocortisone (cortisol replacement medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Hydrocortisone

The elimination half-life of hydrocortisone is approximately 90 minutes (1.5 hours) when administered orally in conventional immediate-release formulations. 1, 2

Pharmacokinetic Properties

  • The plasma half-life ranges from 76.5 minutes on average, with individual variation spanning 40-225 minutes in patients with adrenal insufficiency, demonstrating significant interpatient variability. 3

  • This short half-life necessitates multiple daily doses (typically 2-3 times per day) to maintain adequate cortisol levels, as conventional immediate-release tablets produce high peaks and low troughs between doses. 1

Clinical Implications of Short Half-Life

  • The brief half-life explains why hydrocortisone is preferred over longer-acting corticosteroids like dexamethasone for physiologic replacement therapy, as it better mimics the natural diurnal cortisol rhythm when dosed appropriately (2/3 morning, 1/3 afternoon). 4

  • Time to plasma cortisol concentration falling below 100 nmol/L averages 289 minutes (range 140-540 minutes) after oral administration, influenced by both absorption rate and elimination half-life. 3

  • Maximum plasma concentration (Cmax) occurs at approximately 67 minutes (range 20-118 minutes) after oral dosing, with substantial interindividual variation. 3

Comparison with Dexamethasone

  • Dexamethasone has a "much longer biological half-life" compared to hydrocortisone, which contributes to its higher relative potency and increased risk of adverse neurodevelopmental effects, particularly in neonatal populations. 4

  • This longer half-life of dexamethasone makes it unsuitable for physiologic cortisol replacement and increases the risk of over-replacement and Cushingoid side effects. 4

Dosing Considerations Based on Half-Life

  • The short 90-minute half-life requires sustained administration every 4-6 hours when high blood levels are needed during stress situations or adrenal crisis. 5

  • Continuous intravenous infusion (200 mg over 24 hours) is superior to intermittent bolus dosing for maintaining physiologic cortisol concentrations during major stress, as it compensates for the rapid elimination. 5, 6

  • Extended-release formulations have been developed to overcome the limitations of the short half-life, enabling once- or twice-daily dosing, though the clinical benefits remain under investigation. 2

Practical Clinical Pitfalls

  • Do not assume standard dosing intervals work for all patients—the 3-fold variation in half-life (40-225 minutes) means some patients may require more frequent dosing to avoid periods of inadequate cortisol coverage. 3

  • Patients with both fast absorption (short tmax) and fast elimination (short half-life) reach subtherapeutic levels most quickly (249.5 minutes), while those with slow absorption but fast elimination paradoxically maintain levels longer (380 minutes). 3

  • The pharmacodynamic effect lags behind pharmacokinetics—maximum suppression of adrenal hormones occurs approximately 3 hours after morning dosing, not at peak plasma concentration. 7

References

Research

Extended-release Hydrocortisone Formulations-Is There a Clinically Meaningful Benefit?

The Journal of clinical endocrinology and metabolism, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Adrenal Crisis in an Unconscious Patient

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Duration of suppression of adrenal steroids after glucocorticoid administration.

International journal of pediatric endocrinology, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.